Modified curcumins as potential drug candidates for breast cancer: An overview
AL Flint, DW Hansen, LVD Brown, LE Stewart, E Ortiz… - Molecules, 2022 - mdpi.com
Breast cancer (BC), the most common malignancy in women, results from significant
alterations in genetic and epigenetic mechanisms that alter multiple signaling pathways in …
alterations in genetic and epigenetic mechanisms that alter multiple signaling pathways in …
Recent advances of curcumin derivatives in breast cancer
Y Yin, Y Tan, X Wei, X Li, H Chen, Z Yang… - Chemistry & …, 2022 - Wiley Online Library
Curcumin is a potential plant‐derived drug for the treatment of breast cancer. Poor solubility
and bioavailability are the main factors that limit its clinical application. Various structural …
and bioavailability are the main factors that limit its clinical application. Various structural …
In vitro synergistic effect of hesperidin and doxorubicin downregulates epithelial-mesenchymal transition in highly metastatic breast cancer cells
ND Amalina, IA Salsabila, UM Zulfin, RI Jenie… - Journal of the Egyptian …, 2023 - Springer
Background We previously reported that in highly metastatic breast cancer cells, doxorubicin
(DOX) at non-toxic concentrations promoted cell migration and invasion. Hesperidin (30, 5, 9 …
(DOX) at non-toxic concentrations promoted cell migration and invasion. Hesperidin (30, 5, 9 …
MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K/AKT pathway
S Wei, Y Zhang, X Ma, Y Yao, Q Zhou, W Zhang… - Scientific Reports, 2023 - nature.com
Triple-negative breast cancer (TNBC), a highly aggressive and heterogeneous subtype of
breast cancer, lacks effective treatment options. Sophora flavescens Aiton, a Chinese …
breast cancer, lacks effective treatment options. Sophora flavescens Aiton, a Chinese …
[HTML][HTML] Chemoprevention curcumin analog 1.1 promotes metaphase arrest and enhances intracellular reactive oxygen species levels on TNBC MDA-MB-231 and …
D Novitasari, RI Jenie, J Kato… - Research in …, 2023 - journals.lww.com
Background and purpose: Previous studies highlighted that chemoprevention curcumin
analog-1.1 (CCA-1.1) demonstrated an antitumor effect on breast, leukemia, and colorectal …
analog-1.1 (CCA-1.1) demonstrated an antitumor effect on breast, leukemia, and colorectal …
Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment: integrated computational analysis and in vitro study
The treatment of glioblastoma multiforme (GBM) is challenging owing to its localization in the
brain, the limited capacity of brain cells to repair, resistance to conventional therapy, and its …
brain, the limited capacity of brain cells to repair, resistance to conventional therapy, and its …
Virtual screening of potential inhibitor against breast cancer-causing estrogen receptor alpha (ERα): molecular docking and dynamic simulations
S Muhammad, A Saba, RA Khera… - Molecular …, 2022 - Taylor & Francis
Breast cancer (Bca) causes the highest rate of mortality in females owing to the out-of-
control cell division in breast cells. In this work, we perform an in-silico screening based on …
control cell division in breast cells. In this work, we perform an in-silico screening based on …
Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies
D Novitasari, I Nakamae, RI Jenie… - Saudi Pharmaceutical …, 2024 - Elsevier
Abstract Pentagamavunone-1 (PGV-1), an analog of curcumin, has been studied for its
cytotoxic effects in 4T1, MCF7, MCF7/HER2, and T47D breast cancer cells. Its …
cytotoxic effects in 4T1, MCF7, MCF7/HER2, and T47D breast cancer cells. Its …
[HTML][HTML] Transcriptomics analyses reveal the effects of Pentagamaboronon-0-ol on PI3K/Akt and cell cycle of HER2+ breast cancer cells
Introduction Monoclonal antibodies and targeted therapies against HER2+ breast cancer
has improved overall and disease-free survival in patients; however, encountering drug …
has improved overall and disease-free survival in patients; however, encountering drug …
Bioinformatic and molecular interaction studies uncover that CCA-1.1 and PGV-1 differentially target mitotic regulatory protein and have a synergistic effect against …
E Meiyanto, D Novitasari, RY Utomo… - Indonesian Journal of …, 2022 - journal.ugm.ac.id
Abstract Numerous studies demonstrated CCA-1.1, the modified compound from PGV-1,
inhibits tumor cells growth in breast and colorectal cancer. This time, we used bioinformatics …
inhibits tumor cells growth in breast and colorectal cancer. This time, we used bioinformatics …